Despite ongoing efforts to better understand the mechanisms underlying safety and toxicity, ~30% of the attrition in drug discovery and development is still due to safety concerns. Changes in current practice regarding the assessment of safety and toxicity are required to reduce late stage attrition and enable effective development of novel medicines. This review focuses on the implications of empirical evidence generation for the evaluation of safety and toxicity during drug development. A shift in paradigm is needed to (i) ensure that pharmacological concepts are incorporated into the evaluation of safety and toxicity; (ii) facilitate the integration of historical evidence and thereby the translation of findings across species as well as between in vitro and in vivo experiments and (iii) promote the use of experimental protocols tailored to address specific safety and toxicity questions. Based on historical examples, we highlight the challenges for the early characterisation of the safety profile of a new molecule and discuss how modelbased methodologies can be applied for the design and analysis of experimental protocols. Issues relative to the scientific rationale are categorised and presented as a hierarchical tree describing the decision-making process. Focus is given to four different areas, namely, optimisation, translation, analytical construct and decision criteria. From a methodological perspective, the relevance of quantitative methods for estimation and extrapolation of risk from toxicology and safety pharmacology experimental protocols, such as points of departure and potency, is discussed in light of advancements in population and Bayesian modelling techniques (e.g. non-linear mixed effects modelling). Their use in the evaluation of pharmacokinetics (PK) and pharmacokinetic-pharmacodynamic relationships (PKPD) has enabled great insight into the dose rationale for medicines in humans, both in terms of efficacy and adverse events. Comparable benefits can be anticipated for the assessment of safety and toxicity profile of novel molecules.
Introduction
The assessment of the safety and toxicity profile of new chemical or biological entities is an integral part of drug development. Despite ongoing efforts to better understand the mechanisms underlying safety and toxicity, ~30% of the attrition in drug discovery and development is still due to safety concerns (1, 2) . Such a high attrition rate is further compounded by the empiricism and entrenched belief which prevails among industry scientists and regulators about the level of evidence and requirements for determining acceptable risk in humans, especially for rare and low frequency events that are associated with potentially irreversible damage.
In addition to its contribution to the attrition rate, safety and toxicity findings have business, legal and societal consequences, which often lead to speculations and even more empiricism in the evaluation and interpretation of experimental data. Whilst a positive benefit-risk ratio should be anticipated and subsequently demonstrated when administering new drugs to humans, the basis upon which inferences are made still lacks the scientific clarity and rigour one would endeavour. The efficiency and value of the current paradigm for the evaluation of safety and toxicity, which relies primarily on standard battery tests at supra-therapeutic exposure levels of the investigational drug, has remained unchallenged by the scientific community. In fact, it is mandated by regulators as a mechanism to minimise liabilities.
A shift in paradigm is required that (i) enables the introduction of pharmacological concepts to the evaluation of safety and toxicity; (ii) facilitates the integration of historical experimental evidence and thereby the translation of findings across species and (iii) promotes the value of experimental protocols tailored to address specific safety and toxicity questions.
In this review, we will focus on the implications of current practice for drug development and consider the scientific and ethical requirements for the evaluation of safety and toxicity, including opportunities to characterise in vivo response to mutations and DNA damage using population modelling approaches. Of particular interest for us is to demonstrate that despite the assumption that preclinical safety and toxicity findings are generally predictive of human toxicity (3) , inefficiencies in the experimental design violate the principle of the 3 Rs (reduction, refinement and replacement) (4) . Descriptive data summaries from empirical experimental protocols must be replaced by a model-based approach by which pharmacokinetic, pharmacodynamic and pathophysiological concepts are integrated in a systematic manner.
Three rather recent examples can be used to illustrate the issues with the current paradigm for the evaluation of safety and toxicity, namely the serious adverse events observed with TGN1412, the increased incidence of myocardial infarction in patients who were prescribed rofecoxib and the hepatotoxicity associated with fasiglifam, a selective G-protein-coupled receptor 40 agonist for the treatment of type 2 diabetes mellitus (5-7). These cases highlight the importance of carefully exploring the dose rationale in humans before committing to Phase IIb and III. In spite of the growing relevance of mechanism-based approaches in drug development, a common feature in these examples is that, none of the programs made use of it to support the prediction of drug effects or select the dose(s) in humans. In principle, mechanism-based modelling in conjunction with some basic pharmacology concepts would have been sufficient to predict the potential consequence of these treatments, whether given as single dose to healthy subjects or chronically to patients; i.e. the first two examples reflect the immediate consequences of primary target engagement and the corresponding effects associated with the relevant (patho)physiological pathways, whereas the hepatotoxicity of fasiglifam shows how the characterisation of secondary targets, such as the affinity for efflux and uptake transporters may provide insight into unwanted secondary pharmacology. Yet, the experimental evidence generated preclinically for these compounds did not take into account the concept of target engagement or exposure-response relationships as the basis for the prediction of clinical findings. Instead, it was the characterisation of the maximum-tolerated dose (MTD) and/or no-adverse effect level (NOAEL) that ultimately drove the design of safety pharmacology and toxicity experiments. The empirical evidence of MTD and NOAEL does not provide insight into the underlying mechanisms and often obscures the translation of findings across species (8) .
According to published reports, the serious adverse events observed after intravenous administration of TGN1412, a novel monoclonal T-cell agonist at the time of the incident, could not have been 'predicted' or inferred from non-clinical data. However, the empiricism in the design of in vitro and in vivo experimental protocols and in the interpretation of the findings clearly shows the disconnection between pharmacology and toxicology. Most importantly, the effects observed with the proposed dosing regimen could have been anticipated even without any experimental data. The failure to predict a systemic inflammatory response by rapid induction of cytokines (a 'cytokine storm') with catastrophic multi-organ failure (5) is not surprising when structure homology, target occupancy and pharmacokinetic principles are disregarded. Despite the availability of in vitro binding assays, there was no attempt to correlate or integrate the results from different experiments. The use of a pharmacokinetic-pharmacodynamic model (PKPD) based on target affinity, agonism theory and predicted drug disposition properties would have been sufficient to make inferences about target site exposure, target activation and downstream pharmacological effects.
Tragedies like this provoke reactive measures from industry and regulators (9) (10) (11) (12) (13) (14) which led to the release of new guidelines for the assessment of preclinical data. However, none of the guidelines have tackled the problem from a scientific perspective. Changes have been introduced to the design of first-in-human studies (12) , which reflect mitigation measures for process-related consequences of safety and toxicity findings. A framework that ensures a more critical appraisal of the scientific rationale, based on pharmacological concepts (i.e. target engagement) is still missing.
Rofecoxib, a selective COX-2 inhibitor prescribed to more than 107 million patients in the USA (15) , is another example of market withdrawal because of so-called 'unexpected' long-term safety findings. Irrespective of the debate that followed after evidence from clinical trial data showed increased risk of myocardial infarction (6), little effort was made to incorporate target engagement concepts into the evaluation of the findings, which could be used to assess whether the extent of COX-2 inhibition (and consequently prostaglandin suppression) observed at the tested dose levels was required for the therapeutic response. Undoubtedly, such an analysis would have allowed one to discriminate between class-effect and dose-related toxicity. Paracelsus highlighted the importance of the dose more than 500 years ago, and yet none of the published reports considered this critical question: did patients receive the optimal dose and dosing regimen for the proposed indications? Clinical and scientific experts dwelled on the realm of toxicity as the result of an off-target event, without exploring in a systematic manner the (obvious) connection to dosing regimen, target exposure, the time course of pharmacological effect, the duration of treatment and physiological role of the substrates for COX-2 in the heart and other tissues (15) (16) (17) . Evidence of an underlying concentration-effect relationship was not gathered or used as basis for interpreting those findings. Instead, allegations of misconduct followed that overruled any comprehensive assessment.
The termination of the clinical development of TAK-875 (fasiglifam) due to the concern about its liver toxicity also shows that knowledge of PKPD properties is not systematically used to translate findings across species (7). Non-renal clearance, including hepatic metabolism, was the predominant route of elimination of TAK-875 (18) . In fact, experimental data indicated that after intravenous administration, high concentrations of the parent compound were observed even at 24-h post-dose. In addition, liver concentrations were found to be three times greater than in plasma. It was shown that serum total bile acids (TBAs) and total bilirubin (conjugated and unconjugated, TBIL) levels increased in these preclinical experiments. Despite evidence that conjugated bilirubin concentrations are indicators of cholestasis, which accounts for ~30% of all cases of drug-induced liver injury (19, 20) , scaling of the findings was not considered as the basis for prediction of the effects in humans.
From a clinical pharmacology perspective, the aforementioned examples reflect the failure in anticipating the biological consequences of target engagement, i.e. establishing PKPD relationships. In fact, post-market withdrawals are not really an uncommon occurrence in the history of the Food and Drug Administration (FDA). From a total of more than 600 new drug approvals between 1975 and early 2012, there have been 35 withdrawals from the USA market due to safety issues in that same period (21, 22) . The withdrawal of a medicinal product seems to have become the expected course of action for regulators and industry who are faced with 'unexpected' safety findings. Interestingly, dosage changes, due to safety occurred in approximately one out five drugs in the period from 1980 to 1999 (23, 24) . This pattern seems to confirm the lack of a well-defined dose rationale.
It is worth mentioning that current practice relies on the dichotomisation of the risk by the point of departure and safety thresholds, instead of characterising the exposure-response relationship as the basis for defining the safe exposure range in humans. As shown in Figure 1 , a hierarchical tree is proposed to describe the different issues one faces when assessing, analysing and translating safety and toxicity into risk in humans. Ultimately, this tree highlights the limitations of empirical evidence when data are presented and summarised in a descriptive manner.
The integration of model-based concepts and PKPD relationships into the rationale for the design, analysis and interpretation of safety pharmacology and toxicology protocols is vital for a paradigm shift. A model-based approach does not only challenge the current views on the role of experimental evidence as the sole basis for the assessment of non-clinical safety; it also enables the use of inferential methods and evidence synthesis in the evaluation of the safety and toxicity profile of a molecule, including prediction of reversible and irreversible cellular, tissue or organ damage at clinically relevant exposure levels. Here, we aim therefore at identifying the pitfalls in current approaches to estimating and predicting adverse effects (AEs) and toxicity in humans. Focus is given to the limitations of safety thresholds and how they affect the assessment of the so-called safe exposure levels. Our objectives may intersect with the message from other reviews of drug safety in humans (25, 26) . Figure 1 . A hierarchical tree describing the different issues which need to be considered during the assessment of the safety and toxicity profile of a new chemical or biological entity. An overview of how experimental data are parameterised and how models could be used as input for extrapolation and decision making is presented in the diagram in Figure 6 .
In the subsequent sections, we will cover a range of methodological and conceptual issues. They are clustered into different levels or categories, starting with the limitations associated with experimental and statistical aspects. For the sake of clarity, different facets of the same problem will be discussed, which relate to four areas of quantitative pharmacology research: (i) optimisation (e.g. accuracy, precision), (ii) translation (e.g. sensitivity, biological substrate, relevance), (iii) analytical construct (e.g. parameterisation) and (iv) decision criteria (e.g. acceptable risk level). Each of these points will be addressed separately.
Non-clinical evaluation of safety and toxicity

Defining variables of interest
The development of a medicinal product is a stepwise process that involves the evaluation of in vitro and in vivo pre-clinical data as well as and human efficacy and safety information. The goals of the non-clinical safety evaluation generally include the characterisation of toxic effects with respect to target organs, dose dependence, relationship to exposure and, when appropriate, potential reversibility of the damage or injury. Toxicity occurs when drug-induced alteration of the biological function overcomes normal repair and homeostatic mechanisms. Toxicity can be measured by its effects on the target (organism, organ, tissue or cell) or indirectly by measuring altered biological function downstream after acute, subchronic or chronic exposure to a chemical or biological entity. Drug exposure is then used as a proxy or surrogate for the undesirable effects. Whereas supratherapeutic levels and different experimental protocols are required for the evaluation of general toxicity, immunotoxicity, genotoxicity, carcinogenicity, phototoxicity, abuse liability, reproductive performance and developmental toxicity, these data ultimately contribute to estimating an initial safe starting dose and dose range for clinical trials in humans, and monitoring of potential adverse events.
From a drug development perspective, however, non-clinical safety and toxicity studies should include drug exposure ranges that will be used in clinical trials, i.e. therapeutic doses. In addition, it should be noted that an adverse event might be linked to a molecule or treatment, irrespective of the experimental evidence of a causal relationship between drug levels and adverse event.
Despite some obvious limitations in current protocols for the assessment of safety and toxicity, the use of empirical safety thresholds such as the no observed adverse effect level (NOAEL) or no observed genotoxic effect level (NOGEL), remain common practice in drug development. Support for the existence of thresholds and point of departure has been argued on biological grounds (27) (28) (29) . The argument is that although any exposure to a chemical will cause some change in the biological system, the change must override homeostatic mechanisms in order for it to be biologically significant. In contrast to the maximum tolerated dose (MTD), which remains the primary endpoint of choice in the evaluation of chronic toxicity, the NOAEL remains a key indicator of risk in non-clinical safety assessment. Definitions of the NOAEL vary from source to source, but the basis behind all of them is the estimation of 'the highest experimental point, without biologically significant AEs that are above baseline' (30) . A similar definition applies to NOGEL (31) . In fact, the experimental findings are used to reflect another threshold, i.e. the underlying no adverse event level (NOEL). The calculation involves determination of the lowest observed adverse effect level (LOAEL) which is the lowest observed dosing level for which AEs are recorded. The NOAEL is the dosing level below this. If no LOAEL is found, then the NOAEL cannot be determined. In these cases 1/10th of the lowest tested dose is sometimes used in place of the NOAEL.
Drug exposure and risk can be represented by a variety of different experimental measures. Usually, in the NOAEL approach, the measures used include the dosing level, area-under concentration time curve (AUC) and/or maximum concentration (CMAX). On the other hand, the benchmark dose (BMD) is an alternative to the NOAEL. The method involves the identification of a model describing the exposure-AE relationship to predict the dose that corresponds to the threshold between non-significant and significant risk of AEs. The BMD is usually expressed as a dose level rather than an AUC or CMAX, but it remains of limited use in Industry (32) . Similarly, the point of departure concept is derived from the observed dose-response data. This point can be the lower bound on the dose for the estimated incidence or change in response level from a dose-response model (BMD), or a NOAEL or LOAEL for the observed incidence, or change in level of response.
Another common measure is the human equivalent dose (HED), which represents the estimated dose level in humans yielding equivalent drug exposure as observed in animals at the safety threshold (32) . In addition, recommendations have been made for the use of the maximum recommended starting dose (MRSD) for the selection of the starting doses in first-in-human studies. The MRSD is believed to minimise the chance of serious adverse events in early clinical studies (11, 32) . Recently, the minimum anticipated biological effect level (MABEL) has also been introduced to supplement the other approaches. MABEL describes the exposure that is anticipated, prior to clinical testing, to produce minimum biological effects (33, 34) .
Given the empirical nature of such safety thresholds, errors in the prediction of safety may arise. Despite the various options, there is still a real safety concern when using thresholds to extrapolate drug exposure levels from animals to humans and to make inferences from short to long-term effects. Unfortunately, empirical approaches continue to be preferred to approaches that are more mechanistic. To cope with inaccuracy and poor precision, safety factors, also known as uncertainty factors, have been incorporated on the top of empirical thresholds. Their application in drug development has become widespread (35) and is detailed within the regulatory guidelines. The purpose of such safety factors is to account for variability and potentially greater toxicity in humans than predicted by the HED using existing approaches. This is to ensure that the safety threshold is beneath the true threshold. The default safety factor is 10, but it can by modified by considering it as a product of more refined uncertainty factors. These comprise; interspecies uncertainty, UF A , interindividual uncertainty UF H , subchronic to chronic uncertainty, UF S , LOAEL to NOAEL uncertainty, UF L , and data adequacy UF D , for when chronic toxicity studies in at least two different species are unavailable (36, 37) . There is also a modification factor where there is a perceived greater risk of toxicity in humans.
It should be noted that even when safety factors are integrated into the estimation of thresholds, the actual risk a treatment represents to humans could be overlooked. Over-conservative attitude may give the wrong perception of caution. Growing evidence in pharmacology research suggests that accurate assessment of risk cannot be performed without some degree of understanding about the extent of target engagement and nature of the ligand (i.e. agonistic or antagonistic) interaction with the target.
Measures of drug exposure used as descriptors of acceptable risk
A consequence of the use of safety thresholds is the estimation of drug exposure or dose levels that can be correlated with the adverse events observed beyond that specific threshold, for which the risk for humans is deemed unacceptable. Numerous assumptions are however required to ensure accurate translation of safety and toxicity findings from animals to humans.
Different measures of exposure are used in reports. Clearly, to have predictive value the drug levels and corresponding AEs in nonclinical experiments must reflect pathophysiological processes and pharmacokinetics in humans. The most basic metrics is dosing level, which is usually expressed in terms of daily dose (e.g. mg/day). The dose, however, may be a poor indicator of response since it does not account for confounders such as bioavailability, differences in metabolic capacity, or other pharmacokinetic processes that alter target exposure on an individual subject level. For this reason, parameters describing systemic drug concentrations are preferred (e.g. AUC and C MAX ), but the choice for those parameters relies on the assumption that rapid equilibration occurs between the drugs levels in the systemic circulation and the target tissue. Given the fragmented process used for the evaluation of pharmacology and toxicology data, the validity of this assumption is questioned even when evidence from pharmacological and pharmacokinetic data indicate otherwise. Differences in systemic and target exposure can also be large in the case of metabolic saturation, when small increments in dose can produce disproportionately large increases in AUC. This can lead to deceptively safe estimates even if the dose is divided by a safety factor. Conversely, the occurrence of metabolic induction may lead to overly conservative dose selection. The impact of nonlinearity on drug exposure is exemplified by lumiracoxib, a selective COX-II inhibitor with nonlinear elimination, which has been withdrawn from the market due to liver toxicity concerns. Hinz et al. (38) have since showed that the concentrations of lumiracoxib required to achieve sustained COX-II inhibition are significantly lower that of the prescribed dose.
In addition to the aforementioned points, we would like to emphasise the implications of the use of systemic levels as compared to target tissue or target organ exposure. Time-dependent processes may take place, which cannot be inferred from conventional measures of exposure. First, one should realise that pharmacokinetic equilibration between plasma and tissue may not always be assumed. Unbound drug concentrations are primarily distributed into tissues. The extent and rate of distribution depend on physicochemical as well as receptor binding properties. The implications of such processes are that irreversible binding, slowly reversible binding and tissue accumulation may not be easily correlated with circulating total concentrations. From a pharmacodynamic perspective, the same considerations must be made when signal transduction and downstream mechanisms are rate limiting for the onset and maintenance of effects (i.e. AEs). Consequently, the use of AUC and C MAX , expressed over the dosing interval may not accurately reflect the underlying relationship between exposure and AEs. The implicit assumption that there is a correlation between drug levels during the dosing interval and risk is suitable mainly for direct and reversible processes; however it is insufficient to account for the complex nature of the pharmacological processes associated with indirect effects, slowly reversible and irreversible binding.
These complexities can be illustrated by pemetrexed-induced neutropenia. Absolute neutrophil count (ANC) is reduced by inhibition of thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase (39) . The trough of the ANC curve occurs between 8 and 9.6 days after dosing (40) , and is followed by an overshoot effect once levels return to baseline ( Figure 2 ). Empirical approaches can be used to quantify the systemic exposure associated with a particular ANC minimum, but these data ignore the complexity of the ANC curve. The time below a threshold ANC may be a more relevant descriptor of risk and will require a different measure (i.e. parameterisation) of drug exposure. Most importantly, in these circumstances the time course of drug effects (onset, duration and washout) often does not correlate linearly with systemic exposure.
Likewise, irreversible binding mechanisms cause drug accumulation at the effect site yielding adverse events that depend primarily on the treatment duration, rather than on systemic drug levels. Measures that do not capture the cumulative nature of these processes may lead to poor correlation between species ( Figure 3 ). In these cases, measures such as cumulative AUC may be more relevant, as it captures the entire dosing history. An example of such an effect is tardive dyskinesia produced by neuroleptic drugs (41) .
Based on the aforementioned examples, it becomes evident that safety factors may not suffice to account for possible inaccuracies in the estimates of safety thresholds. Time-dependent PKPD processes cannot be factored in by such an empirical approach. Accurate translation of the toxicity findings across species requires the use of mechanism-based approaches to assess the implications of differences in pharmacokinetics, pharmacodynamics as well as in pathophysiology. Of particular importance is the fact that interspecies variability in metabolic rate and capacity can lead to completely different safety profiles across species if metabolites are the moiety which determines the adverse events. Likewise, molecules that are substrate to active transporters, carrier-mediated processes and other distribution mechanisms with known species-specific differences will show discrepancies in their clinical safety profile.
Statistical and biological limitations of point estimates
From a statistical perspective, safety thresholds for a population are often presented as point estimates. This ignores variability, which can be decomposed into two parts: variability associated with the estimation methods and real variability in the effects observed between and within subjects. There is also lack of best practice in statistical inference, as risk is inferred from toxicology results using statistics that may be imprecise or inaccurate. Instead, statistical summaries should provide an estimate of the underlying parameters reflecting physiological processes and/or pharmacokinetics. The implications of such practice can be illustrated by the comparison between sample standard deviation and population standard deviation. The former is a statistic and the latter is the inferred parameter.
The equivalent for NOAEL is the adverse effect level (AEL). Based on statistical concepts, it can be shown that meaningful and useful reporting of toxicology findings should include the estimate of AEL with its precision (standard errors). However, the use of an empirical approach prevents the estimation of uncertainty in the AEL. In addition, summary statistics, instead of model parameters for decision-making, lead to the assumption that the estimate is of sufficient precision to give sufficiently narrow confidence intervals. This limitation is believed to be mitigated by the incorporation of safety factors; an assumption which we dispute. The predicted parameter precision for the frequency of AEs given a sample size, n and a risk of AE, p, is determined by the mean standard deviation of the binomial distribution B(n,p). Specifically, the coefficient of variation (CV%) can be calculated via CV% = 100 1-p np . As shown in Table 1 , the parameter precision for the probability of an AE varies from 1580 to 67%, depending on group size and risk. In spite of such large discrepancies in precision, only the number of animals in a group exhibiting an adverse event is reported. Clearly, the performance of this estimator is highly dependent on the underlying risk of the AE in question and the sample size used in the experimental protocol. Another aspect regarding variability estimates is the real variability in the data. Since sampling in toxicology is often very sparse, exposure levels are calculated from satellite groups, which mirror the dosing levels of the animals assigned to the primary treatment group. This ignores real differences that may be present between the two groups. It is equivalent to assuming that all animals have the same exposure and variability in exposure or the underlying physiological processes is not responsible for variability in drug effects.
Given that human variability is typically larger, it is important to understand the role of the different sources of variability. Without quantification of the variability and identification of influential covariate factors, it becomes difficult to predict which groups are more prone to overexposure or more sensitive to AEs. Furthermore, depending on the actual distribution of drug exposure, the distribution of AEs in this group may not be representative of the risk posed to the overall target population. This is not limited to PK variability; pharmacodynamics can be more variable and differences have a greater potential for harm than pharmacokinetic differences. In this case, hypersensitive subpopulations can be completely missed. This is the case of abacavir-induced rash, possibly lumiracoxib and other dose-independent reactions associated with receptor or target polymorphism (42) (43) (44) (45) .
Finally, it should be noted that empirical approaches remain prone to bias. For example, the mean NOAEL is only unbiased if its underlying distribution is normal. This assumption contrasts with the current understanding of pharmacokinetic processes, which are best described by lognormal distributions. Without an explicit rationale, the choice of measures of central tendency remains questionable.
Mechanism-based assessment of safety, toxicity and risk
Whilst regulatory policies for the non-clinical evaluation of medicinal products were introduced at a time when our understanding about receptor pharmacology and pathophysiology was limited, they are no longer justifiable without appropriate update. The concept of safety thresholds as well as the measures of exposure currently used as proxy for acceptable risk cannot be deemed absolute: they rely upon numerous assumptions, which may not hold true in a considerable number of cases. It should be evident that despite the challenges in establishing the causal chain between target engagement and AEs, efforts should be made to ensure the identification of a mechanistic link between relevant measures of exposure and risk. This concept can be implemented even in the absence of understanding of the target or mechanism underlying a given adverse event or undesirable effect. Simulation scenarios can be used to explore PKPD relationships and identify the rate limiting step in the chain of events from dose to AE. Moreover, it should be noted that safety and toxicity findings may not solely depend on drug exposure, but also on the extent of target activation or AEs were assumed to be independent binary events. The estimator is the number of animals as a percentage of n. Values represent the coefficients of variation (CV%).
inhibition, post-receptor amplification and signal transduction processes as well as homeostatic mechanisms. For instance, drug concentrations may be a poor predictor of risk relative to biomarker levels when signal transduction is the rate limiting step for a given AE. It is unfortunate that despite the wide discussion regarding the use of biomarkers in the literature (46) (47) (48) , their application for the evaluation of safety has been limited in drug development.
In Table 2 , defines adverse drug reactions according to seven different categories, which account for the underlying chain of events. The different categories nicely match the mechanistic classification of biomarkers proposed by Danhof et al., as such could be integrated into a new paradigm for the evaluation of non-clinical safety and toxicity (46) .
As it can be seen in Figure 4 , biomarkers can be associated or linked to one of the adverse drug reaction types in Rawlins and Thompson's classification (Table 2) . Undoubtedly, these concepts allow the causal chain of events to be correlated to the time course of overt symptoms and signs in a quantitative manner. In the next paragraphs, we will highlight how distant these concepts are from the approaches currently used in the assessment of non-clinical safety and toxicity.
Minimum anticipated biological effective level
The assessment of the minimum anticipated biological effect level (MABEL) represents one of the first attempts to identify mechanismbased measures of exposure. In the calculation of the MABEL any biomarker can be used, e.g. receptor occupancy or downstream markers such as physiological mediators (34) . This has the advantage of allowing the integration of pharmacodynamic measures that correlate to any target-related toxicity (i.e. including off-target or secondary target effects) when pharmacokinetic processes are not the rate limiting step. The concept relies on the assumption of some knowledge of the putative targets underlying the adverse event to accurately interpret (patho)physiological effects ( Figure 5 ). However, since the MABEL is defined in terms of a biological effect, not toxicity, it is not a measure of risk or a replacement of the NOAEL. Current practice is therefore to use the NOAEL as a measure of risk to guide maximum doses in dose escalation studies, but the maximum recommended starting dose in First Time in Human studies (FTIH) should now be no higher than both the MABEL and the NOAEL-derived MRSD. If the NOAEL, with the addition a safety factors, were indeed protective, such a measure would be an unnecessary. Yet, one needs to acknowledge that the MABEL is simply a retrospective risk-mitigation measure that can account for some of the deficiencies of the NOAEL approach.
Limitations in experimental design
A number of methodological issues need to be addressed to allow wider use of the MABEL or any other mechanism-based measures of 'acceptable risk'. First, one needs to establish the predictive or prognostic value of statistical correlations. Five important criteria need to be satisfied namely: selectivity, specificity, sensitivity, reproducibility and clinical relevance. Currently, despite the possibility of establishing correlations between biomarker and effects, very little effort has been made to quantify estimators such as false positive and false e.g. Anaemia due to glucose-6 phosphate dehydrogenase deficiency Anti-oxidant drugs Type 'C' reactions: These reactions are associated with long-term drug therapy e.g. Benzodiazepine dependence and Analgesic nephropathy. They are well known and can be anticipated Type 'D' reactions: These reactions refer to carcinogenic and teratogenic effects. These reactions are delayed in onset and are very rare since extensive mutagenicity and carcinogenicity studies are done before drug is licensed Type 'E' reactions: The end of treatment or rebound effects Type 'F' reactions: Failure of treatment Type 'G' reactions: due to genetic polymorphism, not immunologically mediated negative rates. For instance, liver enzyme levels provide an example of a biomarker which has high sensitivity but poor specificity (50) . Interestingly, despite the aforementioned limitations clinical scientists and pathologists will defend the value of ALT, AST and bilirubin as better predictors of risk, as compared to drug exposure. Another aspect of interest is the fact that according to current practice, if e.g. elevated liver enzymes are observed in one individual and acute liver failure in another, an empirical framework ignores the correlation between these adverse events. It may be treated as the same adverse event (i.e. 100% correlation), or as two different adverse events (i.e. uncorrelated). The statistical methods and summary measures of toxicity are unable to account for the partial correlation or interaction between events within or between individuals. Thus, the question is why does one not go further along the causal chain of toxicity for all adverse events, instead of relying on measures of systemic exposure? The answer probably lies in that pharmacokinetics is seen as the primary step along the way for most adverse drug reactions. It is a simple, general purpose measure which fits the criterion of providing predictive value for many adverse events, despite the exceptions, for which it will perform poorly.
From a theoretical point of view, another issue that deserves attention is the expected precision of estimates describing the AE frequency. The probability of AE detection is given by (1 − p) n for frequency estimates with sample size, n and risk of AE, p (see Table 3 ). Table 3 shows that empirical approaches perform poorly for adverse events with low incidence. Based on the aforementioned, it is clear that empirical data analysis does not provide uncertainty estimates to properly account for Type I (false positive) and Type II (false negative) error rates. According to this paradigm, the absence of adverse events within the experimental group implies that risk is not present at all. In addition, safety findings are evaluated in an experimentby-experiment basis. This leads to misrepresentation of the estimated population characteristics, which imposes the need for conservative safety factors to account for bias and uncertainty. An immediate consequence of such practice is illustrated by the safe dose levels identified for tolcapone (51) , cerevastin (52) and ximelagatran (53) , which were deemed 'well-tolerated', but were later shown to be unsafe (54) . These examples make evident that the classification of a dose level as 'well tolerated' ignores the high incidence of false negative results in standard designs.
Another problem is the fixed protocol design used for in the estimation of the safety thresholds, which relies on a set of dose levels selected in an arbitrary manner. Consequently, the NOAEL is limited to one of the experimental dose levels. Attempts to overcome the uncertainty and bias in the results may prove ineffective even if the number of animals is increased per group. In addition to the dose selection, the duration of the experiments also requires careful consideration and must be factored accordingly into the estimation of safety thresholds. In general, toxicology studies in animals, performed at supratherapeutic doses over shorter periods are deemed representative of therapeutic doses administered chronically in humans. This assumption has weak pharmacological foundation, especially when considering cases in which the time-to-onset of AEs is unrelated to dose (e.g. neutropenia) (55) . Furthermore, at high doses effects may merely be due to secondary pharmacology.
On the other hand, certain effects that can occur at therapeutic levels may be overlooked at higher exposures. In addition, if toxicity is delayed, then the likelihood of false negatives will increase if recording of AEs stops at the end of dosing. This situation clearly shows that short term studies are in fact 'more unsafe' than longterm studies resulting in higher level of uncertainty or safety factors. A historical example is the case of methylmercury-induced dendritic degeneration in cats (56) . Daily dosing for 2 months results in no differences from control groups up to month 5, when a significant difference becomes evident. If observations had ceased at month 2, this effect would have been missed.
From a statistical perspective, the occurrence of AEs can be viewed as a multidimensional random process over time, with one dimension for each type of AE. In the calculation of the NOAEL, these dimensionalities are reduced to binary processes, leading to loss of information for data arising from continuous processes. Data loss also occurs when all these binary processes are combined and reduced to a single binary number for each individual: the animal either had an AE or it didn't. Information about which adverse event occurred, the time-to-onset, duration, frequency and severity is all lost. On top of this a further reduction happens at group level whereby the binary numbers for each individual are combined and reduced to a single binary number: an AE occurs at a given dose level, or it does not.
The characterisation of safety thresholds prevents the use of quantitative methods, as evidence arising from the number of animals that exhibit adverse events is ignored. Consequently, important information about the relationship between dose, exposure and AEs may be lost. By contrast, an approach that involves longitudinal statistical Summary data reflect the occurrence of adverse events according to a Bernoulli random variable. For different incidence rates, values represent the probability of detecting an AE in protocols with different an experimental group sizes (n). modelling of continuous and categorical data has the potential to use all the data without any loss of information. Among these methods, the BMD has been proposed (57) as an alternative method to the NOAEL. The BMD yields evidence about the entire dose-response curve, rather than a single point. However, relevant data across experimental groups are usually not collated and analysed together (58) . The BMD approach has been considered the preferred point of departure (PoD) for quantitatively describing toxicology data. In fact, PoDs can be used to derive reference doses and margin of exposure values that may be useful for evaluating human risk. These metrics have gained relevance in recent years and are now embedded into regulatory guidelines. Yet, definitions of empirical dose-response models, BMD models, and even mechanism-based dose-response models tend to be oversimplified in current guidelines (59) . For instance, the PoD is derived from the observed experimental data and extrapolated to lower exposures, based on a compound's mode of action. Often, linear approaches (i.e. linear low-dose extrapolation from the PoD to origin) continue to be used despite increasing recognition that non-linear dose responses are observed for at least some substances. In addition, several recent publications have demonstrated that biologically meaningful, sublinear dose-response functions exist for compounds with genotoxic and mutagenic properties (60, 61) . This recognition has contributed to an increasing appreciation of the utility of the quantitative analysis of dose-response relationships in regulatory decision making. Further details about these methodologies can be found elsewhere (59, 62) .
Additional flaws in the empirical evaluation of safety and toxicity
From a scientific and clinical point of view, one of the main disadvantages of empirical approaches is that extrapolation beyond the experimental setting is often unreliable. Paradoxically, the ability to extrapolate or make inferences is central for the evaluation of safety and toxicity. Non-clinical data are generated with the primary objective of data extrapolation in mind. Another limitation that cannot be easily circumvented is the inability to parameterise risk in a systematic manner, accounting for what is observed and what can be inferred from an intervention, irrespectively of the available experimental evidence. For instance, it may not be possible to assess the implications of an AE arising from two different mechanisms of actions. To make accurate extrapolations, any relevant differences in the mechanism of action would have to be incorporated into the analysis and interpretation of the data. A similar problem arises in the case of nonlinear pharmacokinetics, when extrapolation to dose ranges outside of experimental ranges can lead to very different exposure levels, as compared to those expected from linear kinetics. Hence, it is evident that extrapolations derived from safety factors are doomed to remain inaccurate without further understanding of the mechanisms underlying the overt symptoms and signs.
Lastly, it is important to bear in mind that empirical methods often do not lend themselves well to integrate data or combine results from multiple experiments. This inflexibility represents another inherent weakness of the current approaches for the evaluation of safety, which clashes with one of the primary objectives of the drug development process, i.e. to reduce uncertainty about the safety and efficacy of a compound (63) .
Safety threshold versus risk or hazard surface
Currently, the use of fixed thresholds as a metric of safety precludes one from describing the continuous processes and phenomena underlying AEs and toxicity. For example, gastric ulceration is dependent on membrane permeability. Interindividual differences in tissue permeability are perceived as interindividual differences in sensitivity to drug effects, i.e. in the exposure which is required to reach a threshold. Based on current practice, the factor driving such differences often remains obscure. More sophisticated approaches have been proposed to incorporate toxicodynamic differences through use of a sensitivity parameter (64) . However, this suffers from the same weakness as the use of a threshold. Furthermore, thresholds offer no mechanistic basis for extrapolation across species, as there is no way to account for interspecies differences in membrane permeability. Consequently, interspecies differences can only be handled by safety factors. Another example is the evaluation of the genotoxic potential of alkylating agents, for which a NOGEL is defined based on the assumption of linearity in the low-dose region. Without characterising the exposure-response relationship, one cannot explain differences between compounds or (patho)physiological conditions. In fact, mechanistic studies reveal that for compounds such as methylnitrosourea, the NOGEL is dependent on the repair of O6-methylguanine by O6MeG-DNA methyltransferase. Inactivation of the enzyme sensitises cells to methylnitrosurea-induced mutagenesis and shifts the NOGEL to the left on the dose axis (65) .
Another immediate difficulty is the lack of consensus on what is defined as an AE and how definitions vary across species. These definitions lead to different safety levels, meaning that safety thresholds are sensitive to definitions of events as adverse or non-adverse rather than the risk associated with them. Therefore, it should be noted that even with agreed definitions, the relevance of a threshold for the assessment of risk is questionable since it mostly relates only to the presence of an AE, rather than its severity. In this context, the shape and slope of the exposure-risk relationship is an important consideration. As the only way to truly eliminate risk is to cease the hazard-causing activity, this is at odds with the choice for a dichotomous response. Safety thresholds can also obfuscate more complicate U-shaped or bell-shaped relationships which may be relevant characteristics for consideration in a risk-benefit analysis.
In summary, it should be clear that despite the binary nature of thresholds, all (patho)physiological processes underlying an AE are continuous processes. In fact, increasing understanding of the mechanisms explaining drug-target interactions (e.g. receptor pharmacology theory) as well as the identification of downstream pathways (i.e. factors determining post-receptor events) offer the possibility of exploring signal amplification using multidimensional response surfaces, rather than thresholds.
Translational toxicology: allometric scaling
The validity of the undertaking associated with experimental protocols in safety pharmacology and toxicity relies on a set of assumptions regarding the correlation between findings in animals and humans. Unfortunately, these assumptions often lack of construct validity to ensure direct comparability of the findings across species.
As indicated previously, uncertainty about differences between species and limited understanding about the relevance of certain effects in humans have lead to the introduction of safety factors into the estimation of safety thresholds. Whilst many supporters of the approach envisage this as a plausible, cautionary measure, it cannot be ignored that in many cases over-conservatism will prevent the development of compounds that otherwise could be innocuous in humans. The challenge is therefore to identify a mechanistic basis for translating non-clinical safety findings or at least making inferences about drug action based on the results in a different species or experimental system (e.g., in vitro or cell culture). Five different dimensions need to be considered for that purpose: (i) differences in pharmacokinetics (i.e. accounting for physiological processes determining drug absorption, distribution, metabolism and elimination); (ii) differences in pharmacodynamics (i.e. accounting for variation or differences in target engagement, activation and downstream amplification of the biosignal); (iii) differences in homeostasis (i.e. accounting for functional capacity and feedback mechanisms which may compensate for drug-induced changes in physiological processes); (iv) differences in response during health versus disease conditions and (v) differences due to drug delivery properties.
Even though understanding about the mechanisms of toxicity may not be obvious or even possible in early drug development, accurate assessment of causality is essential for extrapolating findings from one species to another. Irrespective, of experimental hurdles, it is also evident that one needs to account for all five dimensions when interpreting or translating non-clinical findings. Yet, focus appears to be given to differences in pharmacokinetics more than any other aspect. As a matter of fact, extrapolation of findings between species often relies on the use of allometric scaling principles (66, 67) . Allometry requires assumptions about the relationships between physiological function (e.g. metabolic capacity) and body size. In principle, a similar concept can be applied to differences in pharmacodynamics (67, 68) , but the use of such techniques in drug development is usually restricted to pharmacokinetic parameters, and more specifically to volume of distribution and clearance.
Despite its wide use in drug development, one needs to be aware of the limitations allometric methods represent to the prediction of pharmacokinetics and pharmacodynamics in humans. First, one needs to realise that different mechanisms may be associated with drug disposition across species. For example, total clearance can result from multiple routes, i.e. metabolism by oxidation and glucuronidation, biliary excretion and/or renal excretion. The use of allometry assumes that when multiple physiological processes are involved, processes are scaled solely based on size differences and processes that do not scale well are considered clinically irrelevant (69) . Biliary excretion is known not to scale well due to the role of ABC transporters expression levels. As such the decision to use scaling is dependent on an overall judgement of its ability to be scaled. For volume of distribution, the assumption is that distribution of drug outside the systemic circulation occurs primarily due to passive diffusion; active transport is not accounted for either. Scaling via more realistic physiologically based pharmacokinetic (PBPK) models (70) , has been shown to account for both size-dependent and size-independent differences. A second source of error in allometric scaling is the assumption that size differences between species is a surrogate for differences in physiological processes. It is functionally equivalent to assuming that a human is a large rodent or another non-clinical species. Furthermore, the scaling of parameters assumes that size-related factors influencing systemic exposure are the only important covariate factors modifying drug effects. Polymorphisms and other changes associated with mutations may be overlooked.
Notwithstanding the flaw in the approach, the evaluation of alternative methods for scaling or translating pharmacokinetics and PKPD relationships remains limited. In fact, size-independent differences compose a much larger part of the differences in pharmacodynamics and this is not accounted for with allometry. Paradoxically, there is also support for the view that size-independent differences are usually small given that adverse events in humans are predictable in the majority of cases (75%) from information obtained from preclinical experiments (71) . This leads to the apparent conclusion that mechanisms of action in animals are similar to humans, even if potentially important differences exist (72, 73) . A related problem is that clinical response is dependent on the underlying disease process, which may be different between species. Differences in baseline (physiological) response and in variability due to disease conditions in humans can confound the measurement of drug-induced effects, as compared to animals. Likewise, differences in target distribution can also complicate the interpretation and translation of non-clinical findings, as in the case of the observed for interspecies differences in drug-induced QT interval prolongation (73, 74) . For example, anaphylaxis is observed in the intestine and liver of rats, but in humans these symptoms are primarily observed in the lungs and blood vessels (75) . The translational gap becomes even larger if one considers psychiatric or other neurological adverse events, which may not be detected in animals.
Translation of risk
Translation of the risk associated with the experimental evidence observed in animals is the ultimate step triggering decisions related to the non-clinical safety and toxicity profile of a novel molecule. Thus far, decision makers rely on expert judgment, which ultimately consists in the use of qualitative or semi-quantitative criteria for the assessment of risk. These criteria informally include some measure of overall uncertainty, but such an approach makes it difficult to understand the propagation of uncertainty from animal to humans. For instance, small physiological changes to the binding levels across species can lead to large changes in estimates of safe exposure, as in the case of gastrointestinal adverse events associated with COX inhibition (76, 77) . Clearly, accurate judgment is even more difficult when dependent on parameters for which uncertainty is unknown or not quantifiable.
Even though these limitations have been acknowledged, some regulators remain reluctant about the use of novel quantitative methods for risk assessment (78) . In reality, there are various reasons why qualitative risk assessment has been advocated over quantitative methods. Many of the argued limitations do not necessarily apply when more modern statistical techniques are considered. We will address some of these points later in the next section, where model-based approaches are discussed.
Informed decisions involve taking both benefits and risks of the drug into account. The danger with the used of safety thresholds to assess risk is that these thresholds do not account for the underlying mechanisms, which in turn could be critical for subsequent clinical interpretation of the adverse events. An encompassing inferential method is therefore needed, which does not only allow for insight into the underlying mechanisms of toxicity, but also enables inclusion of already available experimental data on drug-and system specific parameters (e.g. in vitro data or previously estimated system specific model parameter from other drugs of a similar class) in a statistically and clinically formal manner.
Non-linear mixed effects modelling
The use of model-based methods has the ability to address many of the aforementioned criticisms pertinent to the design and analysis of safety pharmacology and toxicology protocols. Nonlinear-mixed effects models are a particular class of mathematical models that comprise stochastic and deterministic components. Although such models are often referred to as population models, they provide insight at the individual level, separating real variability from estimation uncertainty. They contain the necessary complexities required to assess risk in a manner that translates into scientifically rigorous decisions. In PKPD data analysis, nonlinear mixed-effects models are a tool for handling repeated-measurement data in which the relationship between the explanatory variable and the response variable can be described by a single function, allowing model parameters to differ between subjects (79). An immediate advantage of the approach is that the within-subject variability for a given individual can be distinguished from the differences between subjects even in the absence of balanced or frequent sampling of the data.
In hierarchical modelling, the term 'mixed' refers to the use of both fixed effects (characterising the typical individual in the population) and random effects (describing the parameter distribution). The latter are divided into two levels: the difference between the individual prediction and the observation (residual error) and the between-subject variability (BSV). There may also be circumstances in which individual parameters vary longitudinally between occasions, randomly or due to some unknown physiological process. In such cases, a third level of variability can be introduced, i.e. the interoccasion variability (IOV).
The general structure of a hierarchical model is as follows:
where y ijk is the j th observation at occasion k in individual i. f() is typically a nonlinear function of the individual parameter P ik and independent variables X ijk . In PKPD modelling, f() is usually then individual prediction of the observation. Independent variables are usually time, dose or drug exposure and demographic covariates. The ε ijk forms the residual variability with variance σ 2 . When the variance is independent of f(X ijk , P ik ), the model is said to have additive variability. On the other hand, when σ is proportional to f(), we have a proportional error model (80) .
For the i th individual, the individual parameters P ik can be described by the expression:
where the individual parameter P ik is described by a log-normal distribution with a typical value, Θ. The η i and k i are the random effects describing the differences between the typical (population) value and the individual parameter value. η i is assumed to be normally distributed with mean zero and variance ω 2 . Among other applications, the use of hierarchical models is justified and appropriate when the data available per individual are sparse. In addition, it is recognised as the most effective method to perform meta-analysis of data arising from different studies or when prior knowledge needs to be integrated for the estimation of model parameters. It allows one to adjust for different variances (e.g. presence of influential factor in a given subgroup in the population) and to explore confounding correlations, when the design of the study correlates with the outcome (e.g. effect of weight versus sex).
Estimation methods
The field of statistical modelling has developed well-established parameter estimation methods, which provide the means not only to estimate the most likely value of the parameters given the data, but also to quantify uncertainty in estimated parameters and model (mis)specification. This ultimately provides us the opportunity to account for limited information and gaps in our knowledge. For example, if there is little information on the relationship between the level of target occupancy and target activation, the corresponding parameters will have an appropriately high uncertainty. This feature is particularly relevant for the estimation and translation of risk as uncertainty can be propagated as high imprecision in exposure-risk relationships. Moreover, the assessment of the propagation of model uncertainty to uncertainty in the risk-benefit profile offers the prospect of efficient data collection.
The standard estimation method for nonlinear mixed effects models has been the maximum likelihood (81) (82) (83) (84) . According to this approach, parameters are treated as random variables with distribution determined by the likelihood function p(y|Θ), which represents the probability of the total data arising given the value of the parameters. The reported value for each parameter is the parameter at the maximum of the distribution, and associated uncertainty given by the variance of the distribution. No data reduction is required; each raw data point directly informs parameter estimation thereby allowing us to make maximal use of the existing data. When multiple studies are available in populations that share common physiological processes or treatments, datasets may be aggregated to support integrated analyses across these studies. Furthermore, model-based data analysis can handle multiple types of observations (e.g. pharmacokinetics and pharmacodynamics) as well as different data types (e.g. continuous and categorical).
Of particular interest for the assessment of safety and toxicity is the possibility of applying extensions of the maximum likelihood, which enable mathematically rigorous incorporation of prior parameter information (e.g. receptor occupancy or blood to plasma binding ratio in vitro to describe in vivo data). The two main methods for achieving this are the penalised likelihood method (85) and Bayesian estimation (86) . In addition, the advent of exact likelihood methods such as the expectation maximisation (EM) methods (87) has increased the reliability of PKPD analyses, especially in the presence of sparse data, as it is often the case of general toxicity protocols.
We should also emphasise that in the context of safety pharmacology and toxicity studies, experimental protocol optimisation represents proper adherence to the three R's (reduction, refinement and replacement). When prior information is available for class-specific parameters, a model-based analysis may allow for a reduction of experimental cohort sizes or burden to animals (88) . This is possible because model-based analyses are inferential in nature.
Model parameterisation: empirical versus mechanistic models
Regardless of the increasing number of modelling examples in biomedical and pharmaceutical research, the use of pharmacokinetic and pharmacokinetic-pharmacodynamic models has remained primarily descriptive. However, the application of such models for the evaluation of safety requires further consideration of their biological plausibility and predictive or prognostic value. For example, instead of using a simple compartmental model to describe the observed phases of drug elimination, one may need to consider a physiologically based pharmacokinetic model (PBPK) (89) . As shown in Figure 6 , such models can be developed by integrating existing in vitro with in vivo experimental data or with other sources of information. Subsequently, in vitro-in vivo correlations may be established and used for extrapolation of PK or PKPD properties (90) .
On the other hand, it is not unusual for components of PKPD models to be statistically correlated with or affected by influential factors. Therefore, it is important that covariate selection is guided by a mechanistic or physiological rationale. There are several methods that allow such an approach (92) (93) (94) (95) . An example in early drug development is illustrated by the work of Dubois et al., who show the PKPD relationship of a new chemical entity can be used to establish the clinical relevance of drug-induced QT interval prolongation in a pre-clinical species. The model allows clear distinction between drug-specific and system-specific properties, enabling scaling and extrapolation from animal species to humans. Most importantly, model parameterisation provides a direct measure of the probability ≥10 ms increase of QT/QTc interval (96, 97) .
More recently, mechanism-based models have evolved to encompass systems pharmacology concepts and as such are being applied to describe disease processes (34) . Statistically, these models include a response variable that characterises the disease status and its progression over time. Different parameterisations can be considered that allow ones to zoom into events occurring at molecular or cellular levels, such as mutation, DNA-damage, and polymorphism, facilitating our understanding of the relationship between genotypical and phenotypical effects (98) (99) (100) (101) . Two recent examples of mechanism-based modelling and systems pharmacology are worth mentioning in which mutation, protein transcription and physiological response are characterised. In the first case a systems pharmacology approach was used by Fang and collaborators to describe plasma glucose regulation. The model includes receptor binding components and target gene mRNA in different organs to account more accurately for receptor/gene-mediated glucocorticoid effects (102) . The approach predicts not only the changes in glucose levels, but also the effects of methylprednisolone on the dynamics of glucocorticoid receptor mRNA, free cytosolic receptor and drug-receptor complex (103) . The second example refers to the work of Michell and Mendes, who apply a mechanistic computational model of human liver iron metabolism, including core regulatory components known to contribute to iron homeostasis. The model describes the dynamics and time scale of the hepatic systems response to iron challenge. Most interestingly, the authors show how the clinical implications of mutations can be evaluated by altering a single reaction parameter that mimics a human haemochromatosis gene (HFE) mutation. The simulation provides a quantitative understanding of the liver iron overload that occurs in this disease (104) .
Simulations, experimental design and optimisation
Extrapolations or model predictions beyond the experimental context are subject to potential model specification bias. This limitation is important given that our primary interest is to analyse data arising from pre-clinical species and eventually from healthy subjects to assess safety and toxicity in patients who will be receiving the same drugs, but in a different therapeutic setting. In PKPD modelling, computer simulation involves the use of statistical models to predict the behaviour and performance of the biological system described Figure 7 . Population pharmacokinetic-pharmacodynamic modelling of the incidence and severity of ulceration in rats. The approach describes adverse events in a parametric manner, by which not only drug levels but also biomarkers are integrated. Plots show the observed and predicted ulcer incidence (left) and severity (right). Dots in the left plot show observed percentage of total animals in each cohort manifesting gastrointestinal tract toxicity. Ulcer severity is measured as % of stomach area affected by ulceration. The shaded area is the 95% prediction intervals, which represents the uncertainty in the population prediction (dotted lines depict the 50 th percentile). In contrast to current practice, which relies on the evaluation of findings from each experimental cohort, model predictions reflect the integration of all available data. These results suggest that ulcer incidence is affected by time-independent, long-lasting or irreversible processes, which may appear only after long-term exposure (110) . by the model (105) . Clinical trial simulations (CTS), i.e. computer simulation of trial protocols, enable the evaluation of the impact of different design characteristics on the outcome of a trial. It can also be used to investigate the implications of uncertainty and variability in pharmacokinetic and pharmacological processes, thereby allowing the assessment of the robustness of the protocol to known uncertainty and variability (106) . More generally, in a CTS it is possible to test the influence of any modelling assumption and design factor beforehand (107) . Recently, an application of pharmacokinetic modelling for the analysis of toxicokinetic data has shown the impact of the approach on the estimation of safety thresholds such as the NOAEL (108) .
Trial design can also benefit from the use of optimal design methodology. The goal of optimal design, specifically the methods known as D-optimality and ED-optimality, is to determine design variables (such as sampling times and dose selection) that optimise the expected information content within the desired resource constraints. A variety of software programs exist that are purpose-built for the optimisation of experimental protocols based on PKPD models (109) . Optimal sampling schedules for toxicity experiments can help increase the precision of drug specific parameters and/or reduce the burden to animals by minimising the number of samples needed. This is desirable from an ethical and scientific perspective, as poor experimental design is known to result in biased estimates. Among other advantages, optimal sampling may facilitate the collection of biomarkers in conjunction with pharmacokinetic data when blood volume is limited. A recent example of the approach is depicted in Figure 7 , where naproxen-induced AEs (ulceration) are described in a parametric manner. Here the authors show the relevance of integrating pharmacokinetics and biomarkers for the evaluation of the safety profile of naproxen (76, 110) .
Conclusions
Attrition rates due to safety and toxicity findings remain high. The current paradigm needs to be revisited to ensure some important methodological concepts become common practice in the evaluation of the safety and toxicity profile of a drug. Quantitative methods that enhance the assessment of PoDs and exposure-response relationships are required to ensure accurate characterisation of safe drug exposure in humans. Current practices fail to support decision making on multiple levels. Firstly, the parameterisation of drug exposure and available metrics of risk are often justified by historical precedents rather than by an informed scientific rationale. These measures are assumed to be predictive of AEs in humans, including so-called discrete and stochastic phenomena such as DNA damage and mutations, despite the fact that in many cases known PK and PKPD properties contradict such assumptions. Evidence clearly shows that empirical protocols remain primarily descriptive rather than explanatory of the observed phenomena and are therefore unsuitable for extrapolation, especially when nonlinearities between exposure and effect(s) exist. Moreover, statistically, the use of point estimates and thresholds prevents the understanding of the consequences of between-subject variability and identification of at-risk subpopulations. This is further compounded by types I and II errors that are not accounted for in the design or analysis of safety pharmacology and toxicity data, both of which are critical for informed decision making.
In summary, our review has highlighted the implications of empirical data generation for the evaluation of safety and toxicity during drug development. A shift in paradigm is proposed that enables the integration of pharmacological concepts into the evaluation of safety pharmacology and toxicity. We also indicate the urgent need to integrate historical evidence, so that findings across species can be effectively translated into risk at therapeutic levels humans. Using recent examples from the published literature, we have shown how model-based methodologies can be applied to overcome many of the current limitations, providing an opportunity for better design and analysis of experimental protocols. Modelling and simulation techniques have become a standard tool for the evaluation of PK and PKPD properties, supporting the extrapolation and prediction of drug disposition and treatment effects in humans. Comparable benefits can be anticipated for the assessment of safety and toxicity.
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